-
iShares U.S. Medical Devices ETF (IHI $61.63)
- $61.63 P/E (TTM): 164.7X Cap: $4.32B
- View IHI Profile
- View Questions on IHI
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Amgen Inc. (AMGN $292.62)
- $292.62 P/E (TTM): 27.03X Cap: $157.53B
- View AMGN Profile
- View Questions on AMGN
-
Intuitive Surgical Inc. (ISRG $481.28)
- $481.28 P/E (TTM): 66.89X Cap: $172.52B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $206.57)
- $206.57 P/E (TTM): 88.33X Cap: $364.91B
- View ABBV Profile
- View Questions on ABBV
-
Stryker Corporation (SYK $381.61)
- $381.61 P/E (TTM): 50.58X Cap: $145.89B
- View SYK Profile
- View Questions on SYK
-
UnitedHealth Group Incorporated (DE) (UNH $308.49)
- $308.49 P/E (TTM): 12.73X Cap: $279.39B
- View UNH Profile
- View Questions on UNH
-
iShares U.S. Medical Devices ETF (IHI $61.63)
- $61.63 P/E (TTM): 164.7X Cap: $4.32B
- View IHI Profile
- View Questions on IHI
Q: I have been reviewing my health care holdings and I am disappointed in the whole sector. Their percentage of my holdings has dropped, and if I rebalance I should be adding another 50% to these holdings. I am unhappy with IHI and UNH, even ISRG is in the doldrums. Your thoughts on adding to the health care sector and these companies/ETFs at this time. Are there other companies much better suited that I am missing. I am tempted to remove the whole sector from my portfolio, as I am comfortable with risk.
-
Health Care Select Sector SPDR (XLV $135.89)
- $135.89 P/E (TTM): 65.74X Cap: $32.87B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $61.63)
- $61.63 P/E (TTM): 164.7X Cap: $4.32B
- View IHI Profile
- View Questions on IHI
Q: Health care as a sector has me puzzled. I was adding to my positions in XLV and IHI during 2023-2024. I was prompted to keep investing thinking demographics would favor growth; that elective medical procedures postponed would come roaring back in the years following Covid. Mostly good companies were held in the above ETFs, and I was comfortable investing also because of familiarity with products and services. Markets have proven me wrong. My cost base is markedly higher than valuations today. XLV is down ~5.25% over the past 12 months (year-to-date return is flat —down -0.05%).IHI, although slightly up ~4.28% YTD, has still not recovered from a 20% drop in 2022. (Losses I show are much greater and are not useable for tax).
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
Current officials in the US admin have no clue on how to go about drug price reforms. Worse: they don’t know that they have no clue. Reforms are necessary; and PBMs are rightly under scrutiny for opaque pricing practices. I say this notwithstanding that UNH has produced the largest dollar loss I have had in several years.
The science and med professionals who DO know how to implement sensible and substantial changes are fired and replaced by sycophantic, subservient ignorant types. Is it therefore prudent now to sell one or both of XLV and IHI and redeploy cash in other areas? OR, would one be giving up at possibly the exact wrong time? Is now finally the time that patience with XLV and IHI has a greater chance of paying off?
-
Gilead Sciences Inc. (GILD $117.99)
- $117.99 P/E (TTM): 24.87X Cap: $146.40B
- View GILD Profile
- View Questions on GILD
-
Intuitive Surgical Inc. (ISRG $481.28)
- $481.28 P/E (TTM): 66.89X Cap: $172.52B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $206.57)
- $206.57 P/E (TTM): 88.33X Cap: $364.91B
- View ABBV Profile
- View Questions on ABBV
-
Johnson & Johnson (JNJ $176.25)
- $176.25 P/E (TTM): 18.89X Cap: $424.46B
- View JNJ Profile
- View Questions on JNJ
-
Eli Lilly and Company (LLY $698.05)
- $698.05 P/E (TTM): 57.06X Cap: $660.67B
- View LLY Profile
- View Questions on LLY
-
Medtronic plc. (MDT $92.81)
- $92.81 P/E (TTM): 25.77X Cap: $118.91B
- View MDT Profile
- View Questions on MDT
-
Stryker Corporation (SYK $381.61)
- $381.61 P/E (TTM): 50.58X Cap: $145.89B
- View SYK Profile
- View Questions on SYK
-
Thermo Fisher Scientific Inc (TMO $487.54)
- $487.54 P/E (TTM): 28.28X Cap: $184.10B
- View TMO Profile
- View Questions on TMO
-
Health Care Select Sector SPDR (XLV $135.89)
- $135.89 P/E (TTM): 65.74X Cap: $32.87B
- View XLV Profile
- View Questions on XLV
-
iShares U.S. Medical Devices ETF (IHI $61.63)
- $61.63 P/E (TTM): 164.7X Cap: $4.32B
- View IHI Profile
- View Questions on IHI
-
Sabra Health Care REIT Inc. (SBRA $18.63)
- $18.63 P/E (TTM): 31.08X Cap: $4.42B
- View SBRA Profile
- View Questions on SBRA
-
Healthcare Realty Trust Incorporated (HR $16.41)
- $16.41 Cap: $5.79B
- View HR Profile
- View Questions on HR
-
iShares U.S. Pharmaceuticals ETF (IHE $69.50)
- $69.50 P/E (TTM): 63.66X Cap: $571M
- View IHE Profile
- View Questions on IHE
-
Catalyst Pharmaceuticals Inc. (CPRX $20.23)
- $20.23 P/E (TTM): 12.26X Cap: $2.47B
- View CPRX Profile
- View Questions on CPRX
Q: There was an article in the Globe and Mail today by David Rosenberg about the aging population and he suggested health care related investments such as health care REITS, pharma, devices, and services. What do you think of this idea and can you give me a few recommendations in canada and the US for each of the 4 categories (health reits, pharma, devices, sefrvices)? A mix of ETFS and individual stocks would be great.
Insiders
Share Information
SEC Filings
News and Media